Want to see ICCC full AI Analyst Report?
ICCC Stock Chart & Stats
$11.03
$0.19(1.72%)
At close: 4:00 PM EDT
$11.03
$0.19(1.72%)
Day’s Range― - ―
52-Week Range$4.52 - $12.10
Previous CloseN/A
Volume8.55K
Average Volume (3M)20.75K
Market Cap
$88.64M
Enterprise Value$95.94
Total Cash (Recent Filing)$8.86M
Total Debt (Recent Filing)$12.45M
Price to Earnings (P/E)119.7
Beta-0.12
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding9,082,197
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)2.05
Price to Sales (P/S)2.01
P/FCF Ratio45.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Revenue GrowthSustained double-digit product growth indicates strengthening demand and broader commercial adoption. Continued expansion in the core portfolio can support operating leverage and provide a durable base for future capacity investments.
U.S. Market Share GainsRising share in the U.S. cattle market suggests improving product competitiveness and customer acceptance. A stronger domestic position can reinforce distribution relationships and create a more durable growth engine than reliance on one-off demand.
Capacity Expansion And LiquidityThe planned manufacturing upgrade addresses supply constraints while increasing potential scale, shortening processing time, and improving costs. Funding most investment with cash and operating cash flow reduces dependence on external capital and supports execution.
Bears Say
Gross Margin CompressionThe margin decline shows that manufacturing performance is not yet consistently translating into profitable growth. Persistent cost shifts and production inefficiencies could limit operating leverage until capacity, yields, and throughput improve.
Manufacturing Execution RiskVolatile output can constrain product availability, raise unit costs, and weaken customer service even as demand grows. The expansion program may alleviate these issues, but its benefits depend on successful installation, process control, and yield improvement.
Thin And Volatile ProfitabilityRecent profitability recovery remains fragile because earnings are thin relative to revenue and the company has experienced multiple loss years. Limited earnings resilience reduces its ability to absorb production setbacks, cost inflation, or slower demand.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.52 and its highest was $12.10 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $88.64M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Nov 12, 2026 which is in 84 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Aug 13, 2026. The company reported $0.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,082,197 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of $0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.798%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
ICCC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $75.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.32%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
ICCC Company Deck
ICCC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful commercial momentum: double-digit product revenue growth (Q2 +11.5%, H1 +20.9%), strong U.S. performance and expanding market share, improved profitability and adjusted EBITDA, and a clearly defined multi‑phase capacity expansion to more than triple production capacity. Offsetting these positives were significant gross margin pressure driven by lower manufacturing output, a recurring cost shift from the discontinued Re-Tain program into COGS, a one-time scrap event (~$150K), and a sharp decline in international sales (–38.9% in Q2). Management presented concrete mitigation steps (yield improvement initiatives, capacity investments, colostrum sourcing programs) and expects to finance most expansion with cash on hand. Overall, the positives (revenue, profitability, working capital strength, and actionable expansion plans) appear to outweigh the operational and margin headwinds, though execution risk remains on manufacturing yields and international ramp.View all ICCC earnings summariesTechnical Analysis
Inovio Pharmaceuticals
―
Arcturus Therapeutics
―
XBiotech
―
PDS Biotechnology
―
Rani Therapeutics Holdings
―
Ownership Overview
4.07% Insiders
3.94% Mutual Funds
1.85% Other Institutional Investors
86.96% Public Companies and
Individual Investors